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Abstract
Background: Use of antiretroviral-based microbicides for HIV-1 prophylaxis could introduce a transmission barrier that
inadvertently facilitates the selection of fitter viral variants among incident infections. To investigate this, we assessed the in
vitro function of gag-protease and nef sequences from participants who acquired HIV-1 during the CAPRISA 004 1%
tenofovir microbicide gel trial.
Methods and Results: We isolated the earliest available gag-protease and nef gene sequences from 83 individuals and
examined their in vitro function using recombinant viral replication capacity assays and surface protein downregulation
assays, respectively. No major phylogenetic clustering and no significant differences in gag-protease or nef function were
observed in participants who received tenofovir gel versus placebo gel prophylaxis.
Conclusion: Results indicate that the partial protective effects of 1% tenofovir gel use in the CAPRISA 004 trial were not
offset by selection of transmitted/early HIV-1 variants with enhanced Gag-Protease or Nef fitness.
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Introduction
The placebo-controlled CAPRISA 004 trial demonstrated a
39% reduction in HIV-1 acquisition through vaginal use of a 1%
tenofovir microbicide gel in women [1]. Previous studies of the
Tenofovir gel Research for AIDS Prevention Science (TRAPS)
cohort, which comprises all 98 incident HIV infections from
CAPRISA 004, reported that tenofovir gel use was not associated
with increased selection of antiretroviral resistance mutations [1]
nor did it alter the number of transmitted/founder variants [2].
However, it remains important to ensure that antiretroviral-based
strategies for HIV prophylaxis do not introduce sieving effects [3]
or result in the selection of viral variants with enhanced fitness or
pathogenesis in individuals with breakthrough infection. The
functional characteristics of an individual’s virus can influence the
disease course [4,5,6,7,8,9,10,11]; as such, inadvertent selection of
fitter HIV-1 strains at or shortly after transmission may have
clinical implications.
While there was no obvious influence of 1% tenofovir gel on the
infecting virus based on pol and env sequencing in the TRAPS
cohort [1,2], it is important to rule out more subtle effects of
microbicide use on transmitted viruses with other genetic or
functional differences. Building on previous studies that demon-
strated substantial inter-individual differences in gag-protease repli-
cation capacity [4,10] and nef function [7,9], we investigated
whether tenofovir gel prophylaxis was associated with differences




This study was approved by the Biomedical Research Ethics
Committee at the University of KwaZulu-Natal (South Africa). All
participants provided written informed consent for samples to be
stored and used for this study. The clinical trials registration
number of the parent trial (CAPRISA004) was NCT00441298.
Study participants and Samples
The Tenofovir gel Research for AIDS Prevention Science
(TRAPS) cohort comprises all 98 participants who acquired HIV-
1 during the CAPRISA 004 microbicide trial [1]. We examined
baseline plasma samples from 31 (of 38; 81.6%) 1% tenofovir gel
and 52 (of 60; 86.7%) placebo gel recipients (84.7% of total
infections) for whom the sample was collected within 6 months of
the estimated date of infection (median [IQR] 37.0 [24.25–55.75]
days post-infection). There was no difference in median time post-
infection between samples from the treatment and the placebo
arms of the trial (37.0 vs. 38.0 days, respectively, p= 0.3).
Gag-protease and nef amplification and functional
assessment
HIV-1 gag-protease and nef gene regions were amplified from
plasma HIV RNA by nested RT-PCR using sequence-specific
primers, and bidirectionally sequenced on an ABI 3730xl
automated DNA sequencer (Applied Biosystems). All sequences
except for one were confirmed as HIV-1 subtype C using the
recombinant identification program (RIP; http://www.hiv.lanl.
gov/content/sequence/RIP/RIP.html). A single individual from
the placebo arm harbored a recombinant subtype A/D infection
and was excluded from subsequent analyses, yielding 31 tenofovir
and 51 placebo recipients for study. Alignment of sequences to the
HIV-1 reference strain HXB2 was performed using an in-house
tool based on the HyPhy platform [12]. Phylogenetic trees were
constructed using maximum-likelihood approaches (PhyML; [13])
and visualized using FigTree (http://tree.bio.ed.ac.uk/software/
figtree/).
Generation of quasispecies-containing recombinant viruses
expressing patient-derived gag-protease sequences in an NL4-3
backbone (described in [4,10]) was successful for 30 tenofovir
(97%) and 45 placebo (88%) participants. In vitro replication
capacity of Gag-Protease recombinant viruses was measured by
flow cytometry using a GFP reporter T-cell assay, and results were
normalized to the HIV-1 subtype B laboratory adapted reference
strain NL4-3 as described previously [4,10].
The nef region was successfully amplified from plasma HIV
RNA for 31 tenofovir (100%) and 48 placebo (94%) participants.
For each participant, a single nef sequence that clustered closely
with the original bulk sequence by phylogenetic analysis was
cloned into the pSELECT-GFPzeo vector (InvivoGen, Inc.). The
ability of each Nef clone to downregulate surface CD4 and HLA-
A*02 molecules was measured by flow cytometry following
transfection of CEM T cells, as described previously [9,14]. All
results were normalized to a positive control Nef clone derived
from HIV-1 subtype B strain SF2. In vitro expression of each Nef
clone was verified in CEM T cell lysates by Western blotting using
two independent primary Nef antisera [9], and results were
normalized to actin and compared to expression of SF2 Nef
control. Western blot band intensities were quantified using
ImageQuant LAS 4000 (GE Healthcare Life Sciences). Gag-
protease and Nef functional measurements were performed in
duplicate in independent experiments and results are reported as
the mean of these measurements.
Bulk gag and clonal nef nucleotide sequences have been
deposited into GenBank, accession numbers KF208740 –
KF208816 for gag, and KF208817 – KF208898 for nef.
Statistical Analyses and power estimates
Wilcoxon rank-sum tests were used to compare Gag-Protease
replication capacity, Nef CD4 downregulation and Nef HLA
downregulation functions between the tenofovir gel and placebo
arms. Spearman’s correlation was used to test concordance
between replicate measurements, and to investigate associations
between viral protein functions and clinical markers of disease
progression (plasma viral load and CD4+ cell counts). Statistical
tests were implemented in Prism 5.0 (GraphPad Software, Inc.).
Conservative power estimates based on a total sample size of 75
and published measures of central tendency from assessments of
subtype C sequences using identical methods [10] indicate that the
current study possesses .80% power to detect functional
differences of 6.5% between trial arms at a=0.05.
Results
To examine whether the use of 1% tenofovir microbicide gel
selected for transmitted/early HIV-1 strains with enhanced fitness,
we assessed the sequence and in vitro function of plasma RNA-
derived gag-protease and nef genes from the majority of incident
HIV-1 infections in the CAPRISA 004 trial. Bulk gag and clonal nef
sequences from tenofovir and placebo gel participants did not
display substantial phylogenetic segregation (Figure 1), ruling out
major lineage effects of viral species that infected the two groups.
Gag-Protease replication capacity was measured for 75 samples
using a recombinant virus GFP reporter T cell assay [4] (Figure 2).
Duplicate measurements of recombinant viral replication capacity
were highly concordant (Spearman’s correlation, r = 0.84 and
p,0.0001, not shown). Replication capacity was calculated as the
slope of increase in the percentage of HIV-infected (GFP+) cells
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from days 3–6 post-infection and normalized to that of the HIV-1
subtype B reference strain NL4-3, such that a value of 1.0 indicates
a replication capacity equal to that of NL4-3, whereas values of
.1.0 or ,1.0 indicate replication capacities higher or lower than
NL4-3, respectively. The replication capacity value of a given
recombinant virus was not influenced by minor differences in the
percentage of infected cells on day 3 (not shown). We observed no
significant difference between the replication capacities of
recombinant viruses encoding Gag-Protease sequences between
individuals who received 1% tenofovir gel (n = 30) versus placebo
(n = 45) (median [IQR] 0.65 [0.59–0.73] and 0.68 [0.62–0.75],
respectively, Wilcoxon rank-sum test, p = 0.2) (Figure 2).
We next assessed the ability of 79 participant-derived Nef clones
to downregulate surface CD4 and HLA class I molecules using a
transient CEM T cell transfection assay [9]. To verify expression
of the plasma-derived nef genes following DNA transfection,
proteins were detected by Western blot using two anti-Nef primary
antibodies and results normalized to cellular actin and compared
to control SF2 Nef (Figure 3A). Of the Nef clones assessed, six (8%)
displayed low expression (,0.25 of SF2 control) as well as poor
CD4 and HLA downregulation functions (,0.4 of SF2 control).
Although it is possible that these six clones represented authentic
nef sequences that would display similar in vivo defects, we
excluded these clones from further analysis because poor in vitro
expression, stability, and function resulting from PCR or cloning
errors could not be ruled out.
For the remaining 73 Nef clones whose steady-state protein
expression levels were comparable by Western blot, we examined
CD4 and HLA downregulation function and normalized results to
that of control SF2 Nef. As such, a value of 1.0 indicates an ability
to downregulate the relevant cell-surface molecule (CD4 or HLA)
to a level comparable to that of the control, whereas values of
.1.0 or ,1.0 indicate downregulation activities higher or lower
than that of SF2, respectively. We observed excellent correlation
Figure 1. Sequence analyses of HIV-1 Gag and Nef from treatment and placebo arms. Maximum-likelihood phylogenetic trees of bulk Gag
sequences (Panel A) and clonal Nef sequences (panel B) from participants who received 1% tenofovir gel (red) or placebo (black) demonstrated no
major clustering between arms of the trial. HIV-1 subtype B reference sequence HXB2 is shown in green.
doi:10.1371/journal.pone.0071758.g001
Figure 2. Replication capacity of recombinant viruses expressing Gag-Protease sequences from 1% tenofovir gel and placebo
participants. Panel A: Replication data are shown for recombinant NL4-3 viruses encoding gag-protease from participants in the 1% tenofovir gel
(red) and placebo (black) study arms, expressed as fold-increase in GFP expression over 6 days, relative to day 2. WT NL4-3 control is indicated in blue.
Panel B: The replication capacities of recombinant viruses encoding participant-derived gag-protease sequences, calculated as the slope of viral
spread normalised to WT NL4-3, are shown. No signifant difference in Gag-Protease function was observed between study arms (Mann-Whitney,
p = 0.2).
doi:10.1371/journal.pone.0071758.g002
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between duplicate measurements (Spearman’s r = 0.85; p,0.0001
and r = 0.86, p,0.0001 for CD4 and HLA downregulation,
respectively). Nef clones from tenofovir gel (N=28) and placebo
(N= 45) participants displayed no significant difference in Western
blot band intensity compared to actin-normalized control SF2 Nef
(median [IQR] 0.76 [0.64–0.86] and 0.79 [0.63–0.92], respec-
tively, p = 0.5). Similarly, no relationship was observed between
Nef Western blot band intensity and CD4 (r = 0.03, p = 0.8) or
HLA (r = 0.1, p = 0.3) downregulation functions. CD4 downreg-
ulation activity was comparable between Nef clones obtained from
1% tenofovir gel and placebo participants (median [IQR] 0.93
[0.73–0.99] and 0.96 [0.89–0.99], respectively, p = 0.2) (Figure 3B).
However, we observed a trend towards lower HLA class I
downregulation function in Nef clones from tenofovir gel
participants compared to those who received placebo (median
[IQR] 0.73 [0.63–0.84] and 0.77 [0.69–0.90], respectively,
p = 0.06) (Figure 3C). We conducted a sensitivity analysis on the
entire Nef dataset (including the six samples with low expression/
Figure 3. Functional analyses of Nef clones from treatment and placebo arms. Panel A: Selected Western blot results depict control SF2
Nef, empty (delta-Nef) plasmid and four samples each obtained from participants in the 1% tenofovir gel and placebo study arms. Panel B: Results for
the CD4 downregulation activity of participant-derived nef isolates are shown, normalized to control SF2 Nef (which is equal to 1.0). Panel C: Results
for the HLA-A*02 downregulation activity of participant-derived nef isolates are shown, normalized to control SF2 Nef (equal to 1.0). No significant
differences in Nef-mediated CD4 or HLA downregulation function were observed between study arms (Mann-Whitney, p = 0.2 and p= 0.06,
respectively).
doi:10.1371/journal.pone.0071758.g003
Figure 4. Association between baseline Gag-Protease replication capacity and HIV-1 clinical parameters at 12-months post-
infection. A modest correlation was observed between early Gag-Protease-mediated replication capacity and plasma viral load (Spearman, r = 0.2,
p = 0.05; Panel A), but not CD4+ cell count (Spearman, r = 0.1, p = 0.4; Panel B), at 12 months post-infection.
doi:10.1371/journal.pone.0071758.g004
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function), which yielded similar results (p = 0.2 and p= 0.06 for
CD4 and HLA downregulation, respectively, not shown). Overall,
when the function of all Nef sequences was assessed together, we
observed a significant correlation between Nef-mediated CD4 and
HLA downregulation activities (Spearman’s r = 0.3, p = 0.007, not
shown).
Finally, we evaluated potential relationships between gag-protease
and nef gene functions and the clinical status of study participants.
No correlations were observed between Gag-Protease replication
capacity and the ability of Nef to downregulate either CD4 or
HLA when data from the trial arms were analyzed separately or
together (not shown). Among the 76 participants for whom HIV-1
clinical measurements were available at 12 months post-infection,
a modest yet statistically significant correlation was observed
between baseline Gag-Protease replication capacity and viral load
at 12 months (Spearman’s r = 0.2, p = 0.05, Figure 4A), but no
such association was observed with CD4+ cell counts at 12 months
post-infection (Figure 4B). Furthermore, no relationship was
observed between baseline Nef-mediated CD4 or HLA downreg-
ulation function and plasma viral load (Spearman’s r = 0.05,
p = 0.7 and r = 0.1, p = 0.4, respectively, not shown), or CD4
count (Spearman’s r = 0.1, p = 0.3; and r =20.09, p = 0.5,
respectively, not shown) at 12 months post-infection.
Discussion
To examine the possibility that transmitted/early HIV-1 strains
with altered function could be inadvertently selected by antiret-
roviral-based microbicide prophylaxis, we assessed plasma RNA
gag-protease and nef sequence and function for the earliest available
time points (median 5 weeks following estimated date of infection)
from participants who acquired infection during the CAPRISA
004 1% tenofovir gel microbicide trial [1]. We observed no
difference in the in vitro replication capacity of recombinant
viruses expressing Gag-Protease quasi-species from individuals
who received tenofovir gel versus placebo. Similarly, the ability of
representative participant-derived Nef clones to downregulate cell-
surface CD4 or HLA class I was not significantly different between
study arms, although Nef clones from participants who received
tenofovir gel exhibited HLA downregulation activities that were
on average 3% lower than those from participants in the placebo
arm (p= 0.06). At present, the biological implications of this
observation remain unclear. Of interest, an earlier study on this
cohort reported that participants in the tenofovir gel arm displayed
higher Gag-specific CD4+ T cell responses [15], raising the
intriguing possibility that reduced Nef function could contribute to
differences in antigen presentation among trial participants.
The modest yet statistically significant correlation between in
vitro Gag-Protease replication capacity and plasma viral load at
12 months in the overall cohort is consistent with previous reports
[4,10] and supports the contribution of gag-protease during HIV-1
pathogenesis. Other groups have reported conflicting associations
between Nef-mediated CD4 or HLA downregulation function and
clinical markers of disease [7,9,16,17]; however, we observed no
association between these factors in our study.
In summary, our analysis of baseline samples from the majority
of incident HIV-1 cases in the CAPRISA 004 trial indicates that
the use of 1% tenofovir microbicide gel was not associated with
significant alterations in Gag-Protease or Nef function in vitro.
The partial protective effects of tenofovir observed in this trial are
therefore unlikely to be offset by inadvertent selection of
transmitted/early HIV-1 variants with enhanced viral fitness.
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